EPIC Results Shed Light On First-Line Ponatinib Risk–Benefit Profile
The primary endpoint of major molecular response at 12 months for ponatinib versus imatinib in patients with newly diagnosed chronic phase–chronic myeloid leukaemia remains undetermined, report the EPIC trial investigators. (Source: MedWire News)
Source: MedWire News - May 18, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Deal still possible in Colombia-Novartis cancer drug talks : minister
BOGOTA (Reuters) - The door remains open for Swiss pharmaceutical company Novartis to reach a deal with Colombia to lower the cost of cancer drug imatinib and prevent the Andean country from allowing generic production of the medication, the health minister said. (Source: Reuters: Health)
Source: Reuters: Health - May 18, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Drug- Induced Pneumonitis: A Rare Complication of Imatinib Mesylate Therapy in Patients with Chronic Myeloid Leukemia
2012Post date: Tuesday, May 17, 2016 - 16:23Books and theses (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - May 17, 2016 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Novartis Earnings Fall on Slide in Cancer-Drug Sales
Novartis said first-quarter earnings fell as the Swiss company plowed investment into new drug launches to offset a sharp dip in sales of its blockbuster cancer medicine Gleevec. (Source: WSJ.com: Health)
Source: WSJ.com: Health - April 22, 2016 Category: Pharmaceuticals Tags: PAID Source Type: news
Novartis profits dip as generic rival challenges cancer drug
GENEVA (AP) — Swiss pharmaceuticals titan Novartis says net income from continued operations fell 13 percent in the first quarter as generic competition cut into sales of Gleevec, one of the first very effective cancer medicines. (Source: U.S. News - Health)
Source: U.S. News - Health - April 21, 2016 Category: Consumer Health News Source Type: news
Novartis delivered solid Q1 despite Gleevec loss of exclusivity
Novartis laid out five priorities for 2016: deliver strong financial results; strengthen innovation; improve Alcon performance; capture cross-divisional synergies; and build a higher-performing organization. Net sales were USD 11.6 billion (-3%, +1% cc) in the first quarter, as volume growth of 7 percentage points more than offset the negative impact of generic competition (-4 percentage points) and pricing (-2 percentage points). (Source: World Pharma News)
Source: World Pharma News - April 21, 2016 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Imatinib-related symptom burden linked to adherence in Indian CML patients
Research shows low adherence to imatinib in Indian patients with chronic myeloid leukaemia, with an association between nonadherence and worse symptom burden related to treatment. (Source: MedWire News)
Source: MedWire News - April 20, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
UCLA scientists pinpoint cancer gene responsible for neuroendocrine prostate cancer
Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have discovered that a protein produced by a cancer gene leads to the development of a deadly, late-stage form of prostate cancer called neuroendocrine prostate cancer. The discovery could be a significant step toward a more effective treatment.
The findings, which were published in the journal Cancer Cell, are particularly important because neuroendocrine prostate cancer does not respond to standard treatments, and men who are diagnosed with the disease typically live for less than a year afterward. Up to one-quarter of t...
Source: UCLA Newsroom: Health Sciences - March 31, 2016 Category: Universities & Medical Training Source Type: news
New hope for a type 2 diabetes cure
The cancer treatment drug Imatinib, otherwise known as Gleevec is approved to treat various forms of cancer, mostly notably chronic myeloid leukemia (CML). However, researchers have stumbled onto another possible use for it, curing type 2 diabetes. The team - made up of scientists from the Scripps Research Institute in United States, South Korea-based company Hyndai Pharm Co., Ltd., the Seoul National University, and Ulsan National Institute of Science and Technology (UNIST) (Source: World Pharma News)
Source: World Pharma News - March 30, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Cancer drug Gleevec holds promise for type 2 diabetes
Stephen FellerULSAN, South Korea, March 28 (UPI) -- The cancer drug Gleevec lowered the level of insulin resistance in mice in a study, and lowered risk of hyperglycemia and obesity, without severe side effects. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 28, 2016 Category: Consumer Health News Source Type: news
New hope for a type 2 diabetes cure
Gleevec, which is used in leukemia medications, holds promise for a dramatically more effective treatment of type 2 diabetes, report scientists. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 28, 2016 Category: Science Source Type: news
New hope for a type 2 diabetes cure
(Ulsan National Institute of Science and Technology(UNIST)) A research team, led by Professor Jang Hyun Choi (School of Life Sciences) of UNIST discovered Gleevec, which is used in leukemia medications, holds promise for a dramatically more effective treatment of type 2 diabetes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 27, 2016 Category: Cancer & Oncology Source Type: news
Real-life data show feasibility of imatinib discontinuation in CML
Italian research shows that long-term imatinib discontinuation is feasible outside of a clinical trial setting for patients with chronic myeloid leukaemia who achieve stable undetectable molecular disease with front-line treatment. (Source: MedWire News)
Source: MedWire News - March 19, 2016 Category: Consumer Health News Tags: Oncology Source Type: news
Secondary non-Hodgkin’s lymphoma a concern for CML patients using TKIs
Patients with chronic myeloid leukaemia who use the tyrosine kinase inhibitor imatinib may be three to four times more likely to develop non-Hodgkin’s lymphoma than the general population, study findings indicate. (Source: MedWire News)
Source: MedWire News - March 19, 2016 Category: Consumer Health News Tags: Oncology Source Type: news
Generic Gleevec will likely cut millions in health costs
HealthDay News Using the generic form of the cancer drug Gleevec could save patients and insurers millions of dollars, a new study suggests. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 18, 2016 Category: Consumer Health News Source Type: news
